The Food and Drug Administration (FDA) has approved Teva’s Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200mg/300mg, the first generic version of Gilead’s Truvada 200mg/300mg. Teva’s product was determined to be bioequivalent and therapeutically equivalent to the reference drug.

Truvada combines emtricitabine and tenofovir disoproxil fumarate, both nucleoside analogue reverse transcriptase inhibitors. It is indicated for use in combination with other antiretroviral agents, for the treatment of pediatric and adult patients (weighing ≥17kg) with HIV-1, and for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually-acquired HIV in high-risk adults.

Emtricitabine and tenofovir disoproxil fumarate used for PrEP must only be prescribed to patients confirmed to be HIV-negative immediately prior to initial use and periodically during use. 

Truvada is also available as 100mg/150mg, 133mg/200mg, and 167mg/250mg strength tablets in 30-count bottles.

Related Articles

Reference

FDA approves first generic Truvada for HIV infection and pre-exposure prophylaxis (PrEP) [press release]. Washington DC: Food and Drug Administration. Published June 8, 2017. Accessed June 16, 2017.

This article originally appeared on MPR